Targeted in vivo labeling of receptors for vascular endothelial growth factor: Approach to identification of ischemic tissue

Circulation

Volumn 108, Issue 1, 2003, Pages 97-103

  Lu, Erxiong ^a   Wagner, William R ^a   Schellenberger, Ute ^b   Abraham, Judith A ^b   Klibanov, Alexander L ^c   Woulfe, Steven R ^c   Csikari, Melissa M ^a   Fischer, David ^a   Schreiner, George F ^b   Brandenburger, Gary H ^c   Villanueva, Flordeliza S ^a,d  

^a University of Pittsburgh   (United States)

^b SCIOS INC   (United States)

^c MALLINCKRODT PHARMACEUTICALS   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Angiogenesis; Hypoxia; Imaging; Isotopes; Receptors

Indexed keywords

BIOLOGICAL MARKER; INDIUM; SERUM ALBUMIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; FEMORAL ARTERY; HINDLIMB; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; MUSCLE ISCHEMIA; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RABBIT; RADIOACTIVITY; SKELETAL MUSCLE; UPREGULATION;

ANIMALS; BINDING, COMPETITIVE; DISEASE MODELS, ANIMAL; ENDOTHELIAL GROWTH FACTORS; FEMORAL ARTERY; HINDLIMB; IMMUNOHISTOCHEMISTRY; INDIUM RADIOISOTOPES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISCHEMIA; LYMPHOKINES; METABOLIC CLEARANCE RATE; MUSCLE, SKELETAL; PREDICTIVE VALUE OF TESTS; RABBITS; RADIONUCLIDE IMAGING; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SCINTILLATION COUNTING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037488614     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000079100.38176.83     Document Type: Article

References (30)

1. Sinusas AJ. The potential for myocardial imaging with hypoxia markers. Semin Nucl Med. 1999;29:330-338.
2. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med. 2002;136:54-71.
3. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Rev. 1997;18:4-25.
4. Brogi E, Schatteman G, Wu T, et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest. 1996;97:469-476.
5. Villanueva FS, Abraham JA, Schreiner GF, et al. Myocardial contrast echocardiography can be used to assess the microvascular response to vascular endothelial growth factor-121. Circulation. 2002;105:759-765.
6. 121 homodimer. Arch Biophys Biochem. 2002;404:126-135.
7. Williams MA, Rapoport H. Synthesis of enantiomerically pure diethylenetriaminepentaacetic acid analogues: L-phenylalanine as the educt for substitution at the central acetic acid. J Org Chem. 1993;5:1151-1158.
8. 121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem. 1995;270:11322-11326.
9. Thieme H, Aiello LP, Takagi H, et al. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes. 1995;44:98-103.
10. Pu L, Jackson S, Lachapelle K, et al. A persistent hindlimb ischemia model in the rabbit. J Invest Surg. 1994;7:49-60.
11. Khorasheh F, Sattari S, Gerayeli A, et al. Application of direct search optimization for pharmacokinetic parameter estimation. J Pharm Pharmacol Sci. 1999;2:92-98.
12. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
13. Li J, Brown LF, Hibberd MG, et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol. 1996;270:H1803-H1811.
14. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/flk and Flt in lungs exposed to acute or to chronic hypoxia: modulation of gene expression by nitric oxide. J Clin Invest. 1995;95:1798-1807.
15. Khaw BA, Gold HK, Yasuda T, et al. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin specific antibody. Circulation. 1986;74:501-508.
16. McGhie AI, Radovancevic B, Capek P, et al. Major histocompatibility complex class II antigen expression in rejecting cardiac allografts: detection using in vivo imaging with radiolabeled monoclonal antibody. Circulation. 1997;96:1605-1611.
17. Tsimikas S, Shortal BP, Witztum JL, et al. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol. 2000;20:689-697.
18. 99mTc-based immunoscintigraphic targeting of proliferating smooth muscle cells. Chest. 1997;111:1684-1690.
19. Goldman SJ. Receptor imaging: competitive or complementary to antibody imaging? Semin Nucl Med. 1997;27:85-93.
20. 99mTc-labeled diadenosine tetraphosphates. Proc Natl Acad Sci U S A. 1998;95:691-695.
21. DeForge LE, Schwendner SW, DeGalan MR, et al. Noninvasive assessment of lipid disposition in treated and untreated atherosclerofic rabbits. Pharmacol Res. 1989;6:1011-1016.
22. 123I-labeled synthetic peptide fragment. J Clin Pharmacol. 1993;33:1039-1047.
23. Narula J, Acio ER, Narula N, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med. 2001;7:1347-1352.
24. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326-336.
25. Ng CK, Sinusas AJ, Zaret BL, et al. Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS 181321) as a tracer of myocardial hypoxia. Circulation. 1995;92:1261-1268.
26. 99mTc-labeled nitroimidazoles (BMS-181321) after regional ischemia and reperfusion. Circulation. 1995;92:1246-1253.
27. 12 in vitro and in vivo. Nucl Med Biol. 1998;25:233-240.
28. Bunting RW, Wilkinwon RA, Callahan RK, et al. Indium-III DTPA-heparin: pharmacokinetics and biodistribution following subcutaneous administration in rat and rabbit. Thromb Res. 1997;88:503-507.
29. Henry TD, Abraham JA. Review of preclinical and clinical results with vascular endothelial growth factors for therapeutic angiogenesis. Curr Interv Cardiol Rep. 2000;2:228-241.
30. Giordano FJ. Angiogenesis: mechanisms, modulation, and targeted imaging. J Nucl Cardiol. 1999;6:664-671.